Bryan Love to Antiviral Agents
This is a "connection" page, showing publications Bryan Love has written about Antiviral Agents.
Connection Strength
1.552
-
Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses. J Manag Care Spec Pharm. 2020 Jul; 26(7):879-886.
Score: 0.608
-
Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. Pharmacotherapy. 2019 12; 39(12):1190-1203.
Score: 0.581
-
Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2016 Feb; 36(2):203-17.
Score: 0.112
-
The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy. Expert Opin Drug Saf. 2015; 14(11):1649-52.
Score: 0.109
-
Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2014 Dec; 34(12):1341-54.
Score: 0.103
-
Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. Pharmacoeconomics. 2020 09; 38(9):927-939.
Score: 0.038